Avisi Technologies Announces $10.7M Capital Raise to Advance Novel Glaucoma Device Development

Avisi Technologies宣布获得1070万美元融资，以推进新型青光眼设备的开发。

• Avisi Technologies announces Series A financing for SAPPHIRE pivotal trial of VisiPlate® novel glaucoma treatment

• Avisi Technologies宣布了用于VisiPlate®新型青光眼治疗的SAPPHIRE关键试验的A轮融资

• Round led by MedVenture Partners with participation from new investors and existing investors

• MedVenture Partners领投，新投资者和现有投资者参与的轮融资

• VisiPlate® shunt features unique design with a novel metamaterial, thinner than a human hair

VisiPlate® 支架采用独特设计，使用比人类头发还细的新型超材料。

REDWOOD CITY, Calif., February 25, 2026-- Avisi Technologies, Inc., an ophthalmic medical device company advancing novel, sight-saving technologies, announces the closing of $10.7M in new financing. The Series A round was led by MedVenture Partners, with participation from new investors Sherpa Healthcare Partners, SNBL-Gemseki, SBI US Gateway Fund, Golden Seeds, and OneOneFive.

加利福尼亚州红木城，2026年2月25日——Avisi Technologies, Inc.是一家致力于推进新型视力保护技术的眼科医疗器械公司，宣布完成了1070万美元的新一轮融资。本轮融资由MedVenture Partners领投，新投资者Sherpa Healthcare Partners、SNBL-Gemseki、SBI美国门户基金、Golden Seeds和OneOneFive参与跟投。

This financing round had strong participation from existing investors, including Good Growth Capital, Accanto Partners, Life Sciences Greenhouse Investment, and Quaker Capital Investments..

本轮融资获得了现有投资者的大力支持，包括 Good Growth Capital、Accanto Partners、Life Sciences Greenhouse Investment 和 Quaker Capital Investments。

The funding will support the company's pivotal clinical trial SAPPHIRE, which received FDA IDE approval in 2025, and further development of Avisi's pipeline which includes novel treatments addressing the entire spectrum of glaucomatous disease. The SAPPHIRE Trial is designed to evaluate the safety and efficacy of VisiPlate® – a novel glaucoma treatment device engineered to sustainably reduce intraocular pressure (IOP) by improving outflow of aqueous.

这笔资金将支持公司关键的临床试验 SAPPHIRE，该试验于2025年获得FDA IDE批准，并进一步推动Avisi的产品线开发，其中包括针对整个青光病谱系的新型治疗方法。SAPPHIRE 试验旨在评估 VisiPlate® 的安全性和有效性，这是一种新型的青光眼治疗设备，通过改善房水流出可持续降低眼内压 (IOP)。

As part of the Series A financing, Justin Fukuyama, MS, MBA, a Partner at MedVenture Partners, joins the company's Board of Directors. 'Glaucoma continues to impose a tremendous burden on patients and healthcare systems,' Justin Fukuyama commented, 'The VisiPlate® device addresses a critical gap in patient care, and we are proud to partner with the team at Avisi Technologies to advance this novel treatment into the clinic.'.

作为A轮融资的一部分，MedVenture Partners的合伙人Justin Fukuyama（理学硕士、工商管理硕士）加入了公司董事会。Justin Fukuyama评论道：“青光眼继续给患者和医疗系统带来巨大的负担。VisiPlate®设备填补了患者护理中的一个关键空白，我们很荣幸与Avisi Technologies团队合作，将这种新型治疗方法推进到临床。”

'Avisi Technologies' innovative meta-materials and design engineering tackles the unmet needs of glaucoma patients,' said Darren Cai, PhD, MBA, Managing Partner at Sherpa Healthcare Partners. 'VisiPlate's unique materials, ultra-thin profile, and multichannel design, has the potential to redefine treatment, maintain healthy eye pressures, and improve outcomes for patients facing limited options.'.

“艾维西科技的创新超材料和设计工程解决了青光眼患者未被满足的需求，”夏尔巴医疗保健合作伙伴的管理合伙人蔡达伦博士、工商管理硕士表示。“VisiPlate的独特材料、超薄外形和多通道设计，有望重新定义治疗方式，维持健康的眼压，并改善面临有限选择的患者的治疗效果。”

The VisiPlate® device is designed with multiple and redundant microchannels to provide sustained aqueous flow while minimizing the risk of blockage and re-intervention. The device is made of ultrathin, biocompatible materials that seek to avoid longstanding reasons for failure of existing glaucoma treatment options.

VisiPlate® 设备设计有多个冗余微通道，可在最小化堵塞和再次干预风险的同时提供持续的房水流动。该设备由超薄、生物相容性材料制成，旨在避免现有青光眼治疗方案长期以来的失败原因。

VisiPlate® has been previously studied in the VITA Trial with long-term follow up data presented at the 2026 American Glaucoma Society Annual Meeting. The SAPPHIRE trial is currently enrolling, with multiple sites open across the US..

VisiPlate®之前已在VITA试验中进行过研究，长期随访数据在2026年美国青光眼学会年会上公布。SAPPHIRE试验目前正在招募中，美国多地的多个研究中心已开放。

Avisi's Founder and CEO, Rui Jing Jiang, said 'Avisi's successful capital raise is a testament to the strong data, steady momentum, and expert team behind the VisiPlate® technology. We look forward to partnering with our world-class investors and clinicians to execute a successful pivotal trial and bring novel, vision-saving technologies to glaucoma patients worldwide.'.

Avisi公司的创始人兼首席执行官江瑞静表示：“Avisi成功融资证明了VisiPlate®技术背后的强大数据、稳定的发展势头以及专家团队。我们期待与世界级的投资者和临床医生合作，开展一项成功的关键试验，为全球青光眼患者带来新颖的、挽救视力的技术。”

About VisiPlate®

关于VisiPlate®

Avisi Technologies' VisiPlate® aqueous shunt is a unique device made of a patented metamaterial that has been designed to be non-fibrotic and is many times thinner than a human hair. The device is both doctor and patient-centric, designed for ease of implantation, longevity, comfort, and aesthetics.

Avisi Technologies的VisiPlate®房水引流装置是一种独特的设备，由一种获得专利的超材料制成，设计为无纤维化，并且比人类头发细许多倍。该设备以医生和患者为中心，旨在实现易于植入、持久性、舒适性和美观性。

Its multiple, redundant microchannels are engineered to provide sustained aqueous flow while minimizing the risk of blockage and re-intervention, both common challenges with currently available glaucoma surgical solutions..

其多个冗余微通道经过设计，可在最小化堵塞和再次干预风险的同时提供持续的水流，而堵塞和再次干预是当前可用的青光眼手术解决方案常见的挑战。

About Glaucoma and Current Treatment

关于青光眼及其当前治疗

Glaucoma is the leading cause of irreversible blindness worldwide, affecting over 133 million people according to Market Scope's 2025 Glaucoma Surgical Device Market Report, and currently has no cure. In glaucoma patients, excess fluid builds up within the eye, increasing pressure on the optic nerve and leading to permanent vision loss.

青光眼是全球不可逆失明的主要原因，根据《Market Scope》2025年青光眼手术设备市场报告，全球受影响人数超过1.33亿，并且目前尚无治愈方法。青光眼患者的眼内会积聚过多液体，增加对视神经的压力，从而导致永久性视力丧失。

Glaucoma is a group of diseases, the most common of which are open-angle glaucoma (OAG) and angle-closure glaucoma..

青光眼是一组疾病，其中最常见的是开角型青光眼 (OAG) 和闭角型青光眼。

OAG often has no early warning signs or symptoms. It occurs when the eye's drainage system (trabecular meshwork) becomes clogged, preventing normal fluid outflow and leading to elevated eye pressure. Without diagnosis and treatment, OAG can cause gradual vision loss over time. Current treatments for glaucoma include medications, lasers, surgeries, and medical device solutions.

OAG 通常没有早期预警信号或症状。它发生在眼睛的引流系统（小梁网）被堵塞时，阻止了正常的液体流出，导致眼压升高。如果不进行诊断和治疗，OAG 会随着时间的推移导致逐渐的视力丧失。目前青光眼的治疗方法包括药物、激光、手术和医疗设备解决方案。

However, these interventions rely on patient compliance, re-treatment, or may fail due to occlusion and scarring over time. There remains a pressing need for safe and effective long-term treatments for glaucoma that improve patient outcomes and quality of life..

然而，这些干预措施依赖于患者的依从性、再次治疗，或者可能由于随着时间的推移发生阻塞和瘢痕而失败。仍然迫切需要安全有效的青光眼长期治疗方法，以改善患者的治疗效果和生活质量。

About Avisi Technologies

关于Avisi Technologies

Avisi Technologies is a clinical-stage medical device company committed to advancing vision care through innovative ophthalmic solutions. The company's portfolio includes state-of-the-art treatments for glaucoma and other ocular conditions. These include its flagship VisiPlate® aqueous shunt, V-001 sustained intraocular drug-delivery platform, and the VisiPlate-S drainage device for treating mild to moderate glaucoma at the time of cataract surgery.

Avisi Technologies 是一家处于临床阶段的医疗器械公司，致力于通过创新的眼科解决方案推动视力保健的发展。该公司产品组合包括治疗青光眼和其他眼部疾病的先进治疗方法。其中包括其旗舰产品 VisiPlate® 房水引流器、V-001 持续性眼内药物递送平台，以及用于在白内障手术时治疗轻中度青光眼的 VisiPlate-S 引流装置。

Avisi has been recognized and supported by numerous organizations, including the National Science Foundation (NSF), the Glaucoma Research Foundation, SXSW, Johnson & Johnson JLABs, Medtech Innovator Accelerator, UCSF Rosenman Institute, and the University of Pennsylvania, among others. Avisi is funded by venture capital investors, angel investors, and scientific research grants.

Avisi 获得了包括美国国家科学基金会 (NSF)、青光眼研究基金会、SXSW、强生JLABs、Medtech Innovator Accelerator、UCSF Rosenman Institute 和宾夕法尼亚大学等众多组织的认可与支持。Avisi 的资金来源于风险投资、天使投资人以及科学研究基金。

For more information, visit avisitech.com..

有关更多信息，请访问 avisitech.com。

VisiPlate® is an investigational device. The VisiPlate® device is for investigational use only, and not yet available for sale.

VisiPlate® 是一种研究性设备。VisiPlate® 设备仅用于研究目的，尚未上市销售。

Contact:

联系：

Media Contact:

媒体联系人：

Seth Harrington

赛斯·哈灵顿

info@avisitech.com

info@avisitech.com

More information on the SAPPHIRE clinical trial

有关SAPPHIRE临床试验的更多信息